50 citations
,
April 2021 in “Frontiers in Immunology” This review discusses neuroimmune communication in skin disorders and peripheral neuropathic pain, highlighting the complex interactions between sensory neurons and immune cells; it reports no new clinical results but suggests potential future therapies.
January 2016 in “Zurich Open Repository and Archive (University of Zurich)” This study concludes that dietary L-serine supplementation shows promise as a long-term therapy for hereditary sensory and autonomic neuropathy type 1, reducing neurotoxic 1-deoxysphingolipid levels and improving symptoms in severe cases.
November 2023 in “Journal of Cosmetic Dermatology” In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
8 citations
,
June 2025 in “Stem Cell Research & Therapy” This review discusses the potential of exosome therapy for treating diabetic peripheral neuropathy but highlights the need for more robust preclinical trials before clinical application.